Pharma companies delist patents from FDA's Orange Book following FTC challenges

Nicole DeFeudis

Editor

At least three pharma companies have requested to pull patents from an FDA database after the Federal Trade Commission challenged more than 100 patents it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pharma companies delist patents from FDA's Orange Book following FTC challenges

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring

Another biotech scoops up asset from China-based Keymed and nabs $180M

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

Phar­ma com­pa­nies delist patents from FDA's Or­ange Book fol­low­ing FTC chal­lenges

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Pharma companies delist patents from FDA's Orange Book following FTC challenges